Table 1.
AML patient samples used in liquid chromatography tandem mass spectrometry (LC-MS/MS). UPN #1 patient blasts were utilized in the patient-derived xenograft (PDX) treatment model.
| Sample | CG1 | Leukemia | Cytogenetic/Molecular Abnormalities | HLA-A typing | Phenotype |
|---|---|---|---|---|---|
| UPN #1 | yes | FAB-M1 | Diploid 46 XX; FLT3-TD; NPM1+; DNMT3A+ | A02:01, A24:02 | CD13/33+; MPO+ |
| UPN #2 | yes | FAB-M1 | Pseudodiploid 46XY; del (5q); CEBPA+ | A02:01, A03:01 | CD33/34/38/117+; HLA-DR+, MPO+ |
| UPN #3 | yes | FAB-M4/M5 | not tested | A02:01 | not tested |
| UPN #4 | no | FAB-M4 | Diploid 46XY; FLT3-TD; NPM1+ | A02:01; A32:01 | CD13/33; MPO+; HLA-DR+ |
| UPN #5 | no | Biphenotypic | Diploid 46XY; t(9;22); BCR-ABL1 | A24:02; A33:01 | CD13/19d/33/34/38+; MPO+; HLA-DR+ |
| UPN #6 | yes | B-ALL | Diploid 46XX; t(9;22); BCR-ABL1 | A02:01; A24:02 | CD10/13/19/33/34/38+; HLA-DR+ |
| UPN #7 | no | B/T-ALL | Hyperdiploid 50XY | A02:01, A03:01 | CD13/19/33/34/38+; HLA-DR+ |
| U937 | no | Monocytic | Complex karyotype (>5 cytogenetic abnormalities) | A03:01; A31:12 | CD13, CD33, CD15, CD11b, CD18 |
| U937-A2 | yes | Monocytic | Complex karyotype (>5 cytogenetic abnormalities) | A03:01; A31:12; A0201 | CD13, CD33, CD15, CD11b, CD18 |
| HL-60 | no | APL | Complex karyotype (>5 cytogenetic abnormalities) | A01:01* | CD13, CD33, CD38, CD117, MPO+ |
| HL-60-A2 | yes | APL | Complex karyotype (>5 cytogenetic abnormalities) | A01:01; A02:01 | CD13, CD33, CD38, CD117, MPO+ |
Abbreviations: UPN, unique patient number; FAB, French-American-British; APL, acute promyelocytic leukemia; MPO, myeloperoxidase.
*
Wild-type HL-60 cell line is missing a haplotype, hence only expresses one allele at the HLA-A locus.